New hemophilia treatment decision in January with Emicizumab (ACE910) from Chugai and Roche / Genentech

M.G.
M.G.
Aug 26, 2017 · 1 min read

I’ve been following the prospects for emicizumab since hearing about it from a relative in Japan. So it was exciting to see this week’s announcement by Genentech (subsidiary of Roche) that the FDA has granted Priority Review for emicizumab as prophylaxis with a once-weekly subcutaneous treatment for adults and children with hemophilia A. The FDA is expected to make a decision on approval in the next six months.

Since it’s a different pathway than standard hemophilia treatments, emicizumab seems like a very optimistic development. It operates indirectly on the factor viii deficiency by bringing together factors IXa and X to restore the workings of the coagulation cascade. The very significant benefits to this treatment are that it lasts a week and is delivered under the skin.

The reason the FDA granted an expedited approval was due to favorable results from two studies of emicizuma called HAVEN 1 (studying adolescents and adults) and HAVEN 2 (studying children under age 12). The HAVEN 2 study shows that of the 19 children receiving emicizumab there was only 1 treated bleed.

Currently it’s for those with inhibitors only, so we’ll be keeping a close eye on its potential for treating the larger Hemophilia A population.

)

M.G.

Written by

M.G.

Welcome to a place where words matter. On Medium, smart voices and original ideas take center stage - with no ads in sight. Watch
Follow all the topics you care about, and we’ll deliver the best stories for you to your homepage and inbox. Explore
Get unlimited access to the best stories on Medium — and support writers while you’re at it. Just $5/month. Upgrade